Summary: EnsoData and Nonin have announced a partnership to offer sleep labs a new home sleep apnea testing solution by combining EnsoData’s AI-powered EnsoSleep PPG software with Nonin’s WristOx2 Model 3150 pulse oximeter. This collaboration aims to enhance the accuracy and accessibility of sleep apnea diagnosis, particularly for underserved populations, by offering sleep labs an affordable, FDA-cleared solution for at-home testing.
Key Takeaways:
- Partnership: EnsoData’s AI-driven EnsoSleep PPG software will be integrated with Nonin’s WristOx2 Model 3150 pulse oximeter, creating a solution for home-based sleep apnea testing.
- FDA-Cleared Technology: The partnership leverages the recently FDA-cleared EnsoSleep PPG software and Nonin’s pulse oximetry technology.
- Improved Access to Diagnosis: This collaboration is designed to address the needs of the underserved sleep apnea population, providing sleep labs with a more accessible and cost-effective option for diagnosing sleep apnea outside of traditional clinical settings.
EnsoData, specializing in healthcare artificial intelligence (AI), and Nonin, a maker of patient monitoring devices including pulse oximeters, announced a partnership to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach.
The partnership will combine the recently US Food and Drug Administration (FDA)-cleared EnsoSleep PPG software as a medical device algorithm with Nonin’s WristOx2 Model 3150 reusable wrist-worn device to offer “sleep labs an affordable solution to test for sleep apnea at home,” according to a release from EnsoData.
Combining Noninvasive Monitoring with AI Platform
Nonin’s WristOx2 Model 3150 devices deliver oxygen saturation and pulse rate readings in challenging conditions, including low perfusion and in motion by using sensors that provide continuous SpO2 monitoring and data recording.
“Customers who choose Nonin choose durability, accuracy, and equity,” says John Hastings, CEO of Nonin Medical, in a release. “Combining our class-leading noninvasive monitoring products with EnsoData’s innovative AI platform will increase patient access to quality diagnosis in the significantly underserved field of sleep apnea.”
EnsoSleep PPG is interoperable with compatible FDA-cleared pulse oximetry devices, which now includes the Nonin WristOx2 Model 3150, allowing the AI to analyze collected data and provide sleep staging and event detection analysis to sleep labs and clinicians using Nonin devices.
“This partnership is an important step toward increasing patient access to quality sleep care,” says Justin Mortara, CEO of EnsoData, in a release. “As a trusted manufacturer of high-quality pulse oximetry solutions, Nonin’s devices provide more innovative hardware options for our customers to use in conjunction with EnsoSleep PPG. We are excited to launch this collaboration and continue to grow the EnsoData network of sleep medicine partnerships.”
ID 45707037 © Nexusplexus | Dreamstime.com
Leave a Reply